Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety

Journal of Medicinal Chemistry

Volumn 40, Issue 2, 1997, Pages 226-235

  Lai, Yen Shi ^a   Mendoza, José S ^a   Jagdmann Jr , G Erik ^a   Menaldino, David S ^a   Biggers, Christopher K ^a   Heerding, Julia M ^a   Wilson, Joseph W ^a   Hall, Steven E ^a   Jiang, Jack B ^a   Janzen, William P ^a   Ballas, Lawrence M ^a  

^a Sphinx Pharmaceuticals Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALANOL; BALANOL DERIVATIVE; CYCLIC AMP DEPENDENT PROTEIN KINASE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION;

AZEPINES; ENZYME INHIBITORS; HYDROXYBENZOIC ACIDS; ISOENZYMES; MOLECULAR CONFORMATION; PROTEIN KINASE C; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15644376393     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960497g     Document Type: Article

References (31)

1. (1) Preliminary communications published in (a) Lai, Y.-S.; Stamper, M. Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorg. Med. Chem. Lett. 1995, 5, 2147-2150. (b) Lai, Y.-S.; Menaldino, D. S.; Nichols, J. B.; Jagdmann, G. E., Jr.; Myllot, F.; Gillespie, J.; Hall, S. E. Ring size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorg. Med. Chem. Lett. 1995, 5, 2151-2154. (c) Lai, Y.-S.; Mendoza, J. S.; Hubbard, F.; Kalter, K. Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure. Bioorg. Med. Chem. Lett. 1995, 5, 2155-2160. (d) Mendoza, J. S.; Jagdmann, G. E., Jr.; Gosnell, P. A. Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogues as inhibitors of protein kinase C. Bioorg. Med. Chem. Lett. 1995, 5, 2211-2216.
2. Preliminary communications published in (a) Lai, Y.-S.; Stamper, M. Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorg. Med. Chem. Lett. 1995, 5, 2147-2150. (b) Lai, Y.-S.; Menaldino, D. S.; Nichols, J. B.; Jagdmann, G. E., Jr.; Myllot, F.; Gillespie, J.; Hall, S. E. Ring size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorg. Med. Chem. Lett. 1995, 5, 2151-2154. (c) Lai, Y.-S.; Mendoza, J. S.; Hubbard, F.; Kalter, K. Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure. Bioorg. Med. Chem. Lett. 1995, 5, 2155-2160. (d) Mendoza, J. S.; Jagdmann, G. E., Jr.; Gosnell, P. A. Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogues as inhibitors of protein kinase C. Bioorg. Med. Chem. Lett. 1995, 5, 2211-2216.
3. Preliminary communications published in (a) Lai, Y.-S.; Stamper, M. Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorg. Med. Chem. Lett. 1995, 5, 2147-2150. (b) Lai, Y.-S.; Menaldino, D. S.; Nichols, J. B.; Jagdmann, G. E., Jr.; Myllot, F.; Gillespie, J.; Hall, S. E. Ring size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorg. Med. Chem. Lett. 1995, 5, 2151-2154. (c) Lai, Y.-S.; Mendoza, J. S.; Hubbard, F.; Kalter, K. Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure. Bioorg. Med. Chem. Lett. 1995, 5, 2155-2160. (d) Mendoza, J. S.; Jagdmann, G. E., Jr.; Gosnell, P. A. Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogues as inhibitors of protein kinase C. Bioorg. Med. Chem. Lett. 1995, 5, 2211-2216.
4. Preliminary communications published in (a) Lai, Y.-S.; Stamper, M. Heteroatom effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorg. Med. Chem. Lett. 1995, 5, 2147-2150. (b) Lai, Y.-S.; Menaldino, D. S.; Nichols, J. B.; Jagdmann, G. E., Jr.; Myllot, F.; Gillespie, J.; Hall, S. E. Ring size effect in the PKC inhibitory activities of perhydroazepine analogs of balanol. Bioorg. Med. Chem. Lett. 1995, 5, 2151-2154. (c) Lai, Y.-S.; Mendoza, J. S.; Hubbard, F.; Kalter, K. Synthesis and PKC inhibitory activities of balanol analogs with a cyclopentane substructure. Bioorg. Med. Chem. Lett. 1995, 5, 2155-2160. (d) Mendoza, J. S.; Jagdmann, G. E., Jr.; Gosnell, P. A. Synthesis and biological evaluation of conformationally constrained bicyclic and tricyclic balanol analogues as inhibitors of protein kinase C. Bioorg. Med. Chem. Lett. 1995, 5, 2211-2216.
5. (a) Nishizuka, Y. The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 1984, 308, 693-698.
6. (b) Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988, 334, 661-665.
7. (c) Parker, P. J.; Kour, G.; Marais, R. M.; Mitchell, F.; Pears, C.; Schaap, D.; Stabel, S.; Webster, C. Protein kinase C - A family affair. Mol. Cell. Endocrinol. 1989, 65, 1-11.
8. (d) Stabel, S.; Parker, P. J. Protein kinase C. Pharmacol. Ther. 1991, 51, 71-95.
9. (a) Castagna, M.; Takai, Y.; Kaibuchi, K.; Sana, K.; Kikkawa, U.; Nishizuka, Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J. Biol. Chem. 1982, 257, 7847-7851.
10. (b) Kikkawa, U.; Takai, Y.; Tanaka, Y.; Miyake, R.; Nishizuka, Y. Protein kinase C as a possible receptor protein of phorbol esters. J. Biol. Chem. 1983, 258, 11442-11445.
11. Bradshaw, D.; Hill, C. H.; Nixon, J. S.; Wilkinson, S. E. Therapeutic potential of protein kinase C inhibitors. Agents Actions 1993, 38, 135-147.
12. The therapeutic potential of developing a PKC isozyme specific inhibitor is now being realized. Recent data show that a PKC β1 and β2 selective inhibitor may have thrapeutic value in diabetic complications. Decreased cytotoxicity due to potent inhibition of only one of the PKC isozymes may be of significant benefit in some diseases. As PKC's relevance in specific diseases evolves, the importance of developing specific inhibitors will yield better therapeutic value for such compounds. See Ishii, H.; Jirousek, M. R.; Koya, D.; Takagi, C.; Xia, P.; Clermont, A.; Bursell, S.-E.; Kern, T. S.; Ballas, L. M.; Heath, W. F.; Stramm, L. E.; Feener, E. P.; King, G. L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996, 272, 728-731.
13. (a) Kulanthaivel, P.; Hallock, Y. F.; Boros, C.; Hamilton, S. M.; Janzen, W. P.; Ballas, L. M.; Loomis, C. R.; Jiang, J. B. Balanol: A novel and potent inhibitor of protein kinase C from the fungus Verticillium balanoids. J. Am. Chem. Soc. 1993, 115, 6452-6453.
14. (b) Isolation of this material from Fusarium merismoides Corda has also been reported in a later publication; see: Ohshima, S.; Yanagisawa, M.; Katoh, A.; Fujii, T.; Sano, T.; Matsukuma, S.; Furumai, T.; Fujiu, M.; Watanabe, K.; Yokose, K.; Arisawa, M.; Okuda, T. Fusarium merismoides Corda NR 6356, the source of the protein kinase C inhibitor, azepinostatin; taxonomy, yield improvement, fermentation and biological activity. J. Antibiot. 1994, 47, 639-647.
15. 50 values 10-20-fold less than what was reported in the literature. Kinetics were performed on the parent balanol compound, and this compound appeared to be competitive with ATP. Also, for a virtual kinetic study resulting in a similar conclusion, see ref 16.
16. (a) Lampe, J. W.; Hughes, P. F.; Biggers, C. K.; Smith, S. H.; Hu, H. Total synthesis of (-)-balanol. J. Org. Chem. 1994, 59, 5147-5148.
17. (b) Lampe, J. W.; Hughes, P. F.; Biggers, C. K.; Smith, S. H.; Hu, H. Total synthesis of (-)- and (+)-balanol. J. Org. Chem. 1996, 61, 4572-4581.
18. Independent of our work, other groups have also completed the total synthesis of balanol; see: (c) Nicolaou, K. C.; Bunnage, M. E.; Koide, K. Total synthesis of balanol. J. Am. Chem. Soc. 1994, 116, 8402-8403.
19. (d) Adams, C. P.; Fairway, S. M.; Hardy, C. J.; Hibbs, D. E.; Hursthouse, M. B.; Morley, A. D.; Sharp, B. W.; Vicker, N.; Warner, I. Total Synthesis of balanol: A potent protein kinase C inhibitor of fungal origin. J. Chem. Soc., Perkin Trans. I 1995, 2355-2362.
20. For some balanol analogs with acyclic azepine replacements, see: Defauw, J. M.; Murphy, M. M.; Jagdmann, G. E., Jr.; Hu, H.; Lampe, J. W.; Hollinshead, S. P.; Mitchell, T. J.; Crane, H. M.; Heerding, J. M.; Mendoza, J. S.; Davis, J. E.; Darges, J. W.; Hubbard, F. R.; Hall, S. E. Synthesis and PKC inhibitory activities of acyclic balanol analogs that are highly selective for PKC over PKA. J. Med. Chem. 1996, 39, 5215-5227.
21. See refs 8a,b and Hollinshead, S. P.; Nichols, J. B.; Wilson, J. W. Two practical synthesis of sterically congested benzophenones. J. Org. Chem. 1994, 59, 6703-6709.
22. See ref 1 and discussion therein.
23. (12) For recent reviews on PKC inhibitors, see: (a) Hu, H. Recent discovery and development of selective protein kinase C inhibitors. Drug Discovery Today 1996, 1, 438-447. (b) Dow, R. L. Progress towards selective inhibition of protein kinase C. Curr. Med. Chem. 1994, 1, 192-203.
24. For recent reviews on PKC inhibitors, see: (a) Hu, H. Recent discovery and development of selective protein kinase C inhibitors. Drug Discovery Today 1996, 1, 438-447. (b) Dow, R. L. Progress towards selective inhibition of protein kinase C. Curr. Med. Chem. 1994, 1, 192-203.
25. Unpublished results.
26. Hu, H.; Jagdmann, G. E., Jr.; Hughes, P. F.; Nichols, J. B. Two efficient syntheses of (±)-anti-N-benzyl-3-amino-4-hydroxyhexahydroazepine. Tetrahedron Lett. 1995, 36, 3659-3662.
27. Basta, P.; Strickland, M. B.; Holmes, W.; Loomis, C. R.; Ballas, L. M.; Burns, D. J. Sequence and expression of human protein kinase C-ε. Biochem. Biophys. Acta 1992, 1132, 154-160.
28. Bronson, D. D.; Daniels, D. M.; Dixon, J. T.; Redick, C. C.; Haaland, P. D. Virtual kinetics; using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms. Biochem. Pharmacol. 1995, 50, 823-831.
29. 2+, phosphatidylinositol and phosphatidylinostol 4,5-biphosphate. Biochem. J. 1993, 291, 627-633.
30. Hannun, Y. A.; Loomis, C. R.; Merrill, A. H.; Bell, R. M. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J. Biol. Chem. 1986, 267, 12604-12609.
31. Kashiwada, Y.; Nonaka, G.; Nishioka, I.; Ballas, L. M.; Jiang, J. B.; Jazen, W. P.; Lee, K. H. Tannins as selective inhibitors of protein kinase C. Bioorg. Med. Chem. Lett. 1992, 2, 239-244.